Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib

dc.contributor.authorShaker, Mohamed E.
dc.contributor.authorGomaa, Hesham A. M.
dc.contributor.authorHazem, Sara H.
dc.contributor.authorAbdelgawad, Mohamed A.
dc.contributor.authorElmesery, Mohamed
dc.contributor.authorShaaban, Ahmed A.
dc.date.accessioned2024-03-07T08:06:53Z
dc.date.available2024-03-07T08:06:53Z
dc.date.issued2023
dc.description.abstractThe sterile inflammatory response mediated by Toll-like receptors (TLRs) 4 and 9 is implicated in the massive hepatic damage caused by acetaminophen (APAP)-overdose. There is a crosstalk between TLR-dependent signaling with other intracellular kinases like phosphatidylinositol 3-kinases (PI3Ks). Nevertheless, the detailed role of PI3Kα is still unknown in hepatic sterile inflammation. Accordingly, the effect of the novel PI3Kα inhibitor alpelisib was investigated in the setting of APAP-driven sterile inflammation in the liver. This was examined by pretreating mice with alpelisib (5 and 10 mg/kg, oral) 2 h before APAP (500 mg/kg, i.p.)-intoxication. The results indicated that alpelisib dose-dependently lowered APAP-induced escalation in serum liver function biomarkers and hepatic necroinflammation score. Alpelisib also attenuated APAP-induced rise in cleaved caspase 3 and proliferating cell nuclear antigen (PCNA) in the liver hepatocytes, as indices for apoptosis and proliferation. Mechanistically, inhibition of PI3Kα by alpelisib limited APAP-induced overproduction of the pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in the blood circulation via switching off the activation of several signal transduction proteins, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), signal transducer and activator of transcription-3 (Stat-3), glycogen Synthase Kinase (GSK)-3β and nuclear factor (NF)-κB. Alpelisib also impaired APAP-instigated immune cell infiltration in the liver via reducing systemic granulocyte/macrophage-colony stimulating factor (GM-CSF) release and reversed APAP-induced abnormalities in the systemic and hepatic levels of the anti-inflammatory IL-10 and IL-22. In conclusion, selective modulation of the PI3Kα activity by alpelisib can hinder the inflammatory response and infiltration of immune cells occurring by APAP-hepatotoxicity.
dc.description.versionpublisheddeu
dc.identifier.doi10.3389/fphar.2023.1212771
dc.identifier.ppn1882872614
dc.identifier.urihttps://kops.uni-konstanz.de/handle/123456789/69544
dc.language.isoeng
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectalpelisib
dc.subjectphosphatidylinositol 3-kinase
dc.subjectacetaminophen
dc.subjecthepatotoxicity
dc.subjectDAMPs
dc.subject.ddc570
dc.titleMitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisibeng
dc.typeJOURNAL_ARTICLE
dspace.entity.typePublication
kops.citation.bibtex
@article{Shaker2023Mitig-69544,
  year={2023},
  doi={10.3389/fphar.2023.1212771},
  title={Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib},
  volume={14},
  journal={Frontiers in Pharmacology},
  author={Shaker, Mohamed E. and Gomaa, Hesham A. M. and Hazem, Sara H. and Abdelgawad, Mohamed A. and Elmesery, Mohamed and Shaaban, Ahmed A.},
  note={Corrigendum:  https://doi.org/10.3389/fphar.2023.1281416 Article Number: 1212771}
}
kops.citation.iso690SHAKER, Mohamed E., Hesham A. M. GOMAA, Sara H. HAZEM, Mohamed A. ABDELGAWAD, Mohamed ELMESERY, Ahmed A. SHAABAN, 2023. Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib. In: Frontiers in Pharmacology. Frontiers. 2023, 14, 1212771. eISSN 1663-9812. Available under: doi: 10.3389/fphar.2023.1212771deu
kops.citation.iso690SHAKER, Mohamed E., Hesham A. M. GOMAA, Sara H. HAZEM, Mohamed A. ABDELGAWAD, Mohamed ELMESERY, Ahmed A. SHAABAN, 2023. Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib. In: Frontiers in Pharmacology. Frontiers. 2023, 14, 1212771. eISSN 1663-9812. Available under: doi: 10.3389/fphar.2023.1212771eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/69544">
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/69544/1/Shaker_2-c7dlayvx92at0.pdf"/>
    <dc:contributor>Gomaa, Hesham A. M.</dc:contributor>
    <dc:contributor>Shaaban, Ahmed A.</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-03-07T08:06:53Z</dc:date>
    <dc:creator>Hazem, Sara H.</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/69544/1/Shaker_2-c7dlayvx92at0.pdf"/>
    <dc:contributor>Hazem, Sara H.</dc:contributor>
    <dcterms:issued>2023</dcterms:issued>
    <dc:contributor>Abdelgawad, Mohamed A.</dc:contributor>
    <dcterms:title>Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib</dcterms:title>
    <dc:contributor>Elmesery, Mohamed</dc:contributor>
    <dc:creator>Elmesery, Mohamed</dc:creator>
    <dc:creator>Shaker, Mohamed E.</dc:creator>
    <dcterms:abstract>The sterile inflammatory response mediated by Toll-like receptors (TLRs) 4 and 9 is implicated in the massive hepatic damage caused by acetaminophen (APAP)-overdose. There is a crosstalk between TLR-dependent signaling with other intracellular kinases like phosphatidylinositol 3-kinases (PI3Ks). Nevertheless, the detailed role of PI3Kα is still unknown in hepatic sterile inflammation. Accordingly, the effect of the novel PI3Kα inhibitor alpelisib was investigated in the setting of APAP-driven sterile inflammation in the liver. This was examined by pretreating mice with alpelisib (5 and 10 mg/kg, oral) 2 h before APAP (500 mg/kg, i.p.)-intoxication. The results indicated that alpelisib dose-dependently lowered APAP-induced escalation in serum liver function biomarkers and hepatic necroinflammation score. Alpelisib also attenuated APAP-induced rise in cleaved caspase 3 and proliferating cell nuclear antigen (PCNA) in the liver hepatocytes, as indices for apoptosis and proliferation. Mechanistically, inhibition of PI3Kα by alpelisib limited APAP-induced overproduction of the pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in the blood circulation via switching off the activation of several signal transduction proteins, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), signal transducer and activator of transcription-3 (Stat-3), glycogen Synthase Kinase (GSK)-3β and nuclear factor (NF)-κB. Alpelisib also impaired APAP-instigated immune cell infiltration in the liver via reducing systemic granulocyte/macrophage-colony stimulating factor (GM-CSF) release and reversed APAP-induced abnormalities in the systemic and hepatic levels of the anti-inflammatory IL-10 and IL-22. In conclusion, selective modulation of the PI3Kα activity by alpelisib can hinder the inflammatory response and infiltration of immune cells occurring by APAP-hepatotoxicity.</dcterms:abstract>
    <dc:creator>Abdelgawad, Mohamed A.</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-03-07T08:06:53Z</dcterms:available>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dc:creator>Shaaban, Ahmed A.</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/69544"/>
    <dc:creator>Gomaa, Hesham A. M.</dc:creator>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Shaker, Mohamed E.</dc:contributor>
    <dc:language>eng</dc:language>
  </rdf:Description>
</rdf:RDF>
kops.description.commentCorrigendum: https://doi.org/10.3389/fphar.2023.1281416
kops.description.openAccessopenaccessgold
kops.flag.isPeerReviewedtrue
kops.flag.knbibliographyfalse
kops.identifier.nbnurn:nbn:de:bsz:352-2-c7dlayvx92at0
kops.sourcefieldFrontiers in Pharmacology. Frontiers. 2023, <b>14</b>, 1212771. eISSN 1663-9812. Available under: doi: 10.3389/fphar.2023.1212771deu
kops.sourcefield.plainFrontiers in Pharmacology. Frontiers. 2023, 14, 1212771. eISSN 1663-9812. Available under: doi: 10.3389/fphar.2023.1212771deu
kops.sourcefield.plainFrontiers in Pharmacology. Frontiers. 2023, 14, 1212771. eISSN 1663-9812. Available under: doi: 10.3389/fphar.2023.1212771eng
relation.isAuthorOfPublication86189790-47b8-46c6-b9c6-b834d3f6d327
relation.isAuthorOfPublication.latestForDiscovery86189790-47b8-46c6-b9c6-b834d3f6d327
source.bibliographicInfo.articleNumber1212771
source.bibliographicInfo.volume14
source.identifier.eissn1663-9812
source.periodicalTitleFrontiers in Pharmacology
source.publisherFrontiers

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
Shaker_2-c7dlayvx92at0.pdf
Größe:
5.32 MB
Format:
Adobe Portable Document Format
Shaker_2-c7dlayvx92at0.pdf
Shaker_2-c7dlayvx92at0.pdfGröße: 5.32 MBDownloads: 53

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
license.txt
Größe:
3.96 KB
Format:
Item-specific license agreed upon to submission
Beschreibung:
license.txt
license.txtGröße: 3.96 KBDownloads: 0